Novavax (NVAX) Profit After Tax (2010 - 2026)
Novavax (NVAX) posted quarterly Profit After Tax of -$9.5 million for Q1 2026, down 101.83% year-over-year from $518.6 million in Q1 2025, and down 154.23% quarter-over-quarter from $17.5 million in Q4 2025.
Novavax (NVAX) Profit After Tax (2010 - 2026) Analysis & Trends
Novavax's Profit After Tax history runs 17 years deep, the most recent figure standing at -$9.5 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 101.83% year-over-year to -$9.5 million; the TTM figure through Mar 2026 stood at -$87.9 million (down 118.35% YoY), while the FY2025 annual figure was $440.3 million, up 334.83% from the prior year.
- Profit After Tax for Q1 2026 stood at -$9.5 million, down from $17.5 million in the prior quarter.
- The five-year high for Profit After Tax was $518.6 million in Q1 2025, with the low at -$510.5 million in Q2 2022.
- The 5-year median for Profit After Tax is -$121.3 million (2024), against an average of -$56.5 million.
- The sharpest annual moves came in 2023 and 2025: Profit After Tax sank 244.49% in 2023, then surged 451.51% in 2025.
- Novavax's Profit After Tax stood at -$182.2 million in 2022, then increased by 2.12% to -$178.4 million in 2023, then soared by 54.58% to -$81.0 million in 2024, then jumped by 121.6% to $17.5 million in 2025, then slumped by 154.23% to -$9.5 million in 2026.
- Business Quant data shows NVAX's Profit After Tax at -$9.5 million in Q1 2026, $17.5 million in Q4 2025, and -$202.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -53.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.39 Mn |
| Mar 31, 2026 | -9.49 Mn |
| Dec 31, 2025 | 17.50 Mn |
| Sep 30, 2025 | -202.38 Mn |
| Jun 30, 2025 | 106.51 Mn |
| Mar 31, 2025 | 518.65 Mn |
| Dec 31, 2024 | -81.03 Mn |
| Sep 30, 2024 | -121.30 Mn |
| Jun 30, 2024 | 162.38 Mn |
| Mar 31, 2024 | -147.55 Mn |
| Dec 31, 2023 | -178.39 Mn |
| Sep 30, 2023 | -130.78 Mn |
| Jun 30, 2023 | 58.01 Mn |
| Mar 31, 2023 | -293.91 Mn |
| Dec 31, 2022 | -182.25 Mn |
| Sep 30, 2022 | -168.61 Mn |
| Jun 30, 2022 | -510.49 Mn |
| Mar 31, 2022 | 203.41 Mn |
| Dec 31, 2021 | -846.28 Mn |
| Sep 30, 2021 | -322.43 Mn |